13F Holdings
中文EN

VBIO Valion Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1787740 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-49.6%
TTM net income YoY-16.9%
TTM EPS YoY—
Revenue 3-yr CAGR-35.8%
Net income 3-yr CAGR—

Margins

Gross margin-58.1%
Operating margin-1,210.8%
Net margin-1,557.3%
FCF margin-1,263.5%
EBITDA margin-1,210.4%

Returns

ROE-240.3%
ROA-156.0%
ROIC (approx.)-1,514.1%
Asset turnover0.10x

Leverage & solvency

Liabilities / assets10.2%
Debt / equity0.00x
Current ratio5.86x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-29.7%
Payout ratio—
Capex / revenue2.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$780,000$1.18M$1.84M$1.26M
Cost of revenue—$778,000$889,000$1.54M$1.29M
Gross profit—$2,000$287,000$299,000-$38,000
R&D expense$3.13M$1.31M$1.66M$1.73M$878,000
SG&A expense$4.77M$3.16M$4.75M$5.88M$2.93M
Operating income-$7.90M-$4.48M-$8.24M-$10.10M-$5.63M
Interest expense$146,000$0———
Pretax income$8.90M$5.70M-$8.24M-$10.10M—
Income tax$0$0———
Net income-$8.88M-$5.66M-$8.24M-$10.10M-$8.49M
EBITDA-$7.89M-$4.47M-$8.24M-$10.09M-$5.62M
EPS (basic)-7.84-19.68-176.80-104.32-2.43
EPS (diluted)—-19.68-176.80-104.32-2.43
Weighted avg. shares (diluted)—287,37046,65096,7783.49M
Banking
Net interest income—$6,000$1,000$2,000-$1.82M
Balance sheet
Cash & equivalents$12.64M$2.00M$3.40M$3.52M$12.97M
Receivables—$69,000$174,000$107,000$92,000
Inventory$0$319,000$756,000$863,000$429,000
Current assets$13.01M$2.64M$4.65M$5.31M$14.29M
PP&E, net$12.64M$2,000$122,000$12,000$11,000
Goodwill$3.46M$0———
Intangibles$2.24M$0———
Total assets$31.61M$2.81M$5.16M$5.88M$15.04M
Current liabilities$646,000$272,000$1.40M$1.88M$1.22M
Total liabilities$7.44M$272,000$1.58M$2.25M$1.76M
Shareholders' equity$16.80M$2.54M$3.58M$3.63M$13.27M
Shares outstanding2.53M556,90286,24196,7789.72M
Cash flow statement
Operating cash flow-$7.00M-$5.72M-$8.51M-$8.92M-$5.61M
Capital expenditure$38,000$0$118,000$11,000—
Free cash flow-$7.04M-$5.72M-$8.63M-$8.93M—
Investing cash flow-$705,000$0-$118,000-$11,000—
Financing cash flow$18.35M$4.33M$8.51M-$528,000$17.54M
Depreciation & amortization$5,000$3,000$8,000$10,000$8,000
Stock-based compensation$564,000$229,000$271,000$398,000$57,000

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.